[
  {
    "objectID": "posts/papers/index.html",
    "href": "posts/papers/index.html",
    "title": "Publications",
    "section": "",
    "text": "üß™ Cancer Immunology Research (AACR) Reuschel, E. L., Sylvester, A., Marcus, S., Wisotsky, S., Dolgoter, A., Reed, K. S., Tan, G. S., Skolnik, J. M., Gillespie, E. (2024). Treatment of Recurrent Respiratory Papillomatosis with DNA immunotherapy INO-3107 induces activation and enrichment of pro-inflammatory CD4+ T cell responses in blood and airways of patients with clinical response\n\n\nAbstract\n\nRecurrent respiratory papillomatosis (RRP) is a chronic, debilitating disease of the airway primarily caused by infection with human papillomavirus (HPV) types 6 and/or 11 and characterized by recurrent, benign tumor growth with potential for malignant transformation. Current standard of care consists of repeated surgical removal of papillomas, which can lead to lasting airway damage and impaired vocal function. Thus, a non-surgical approach to treat RRP is paramount. Previously, we described CD8+ T cell responses associated with clinical response to INO-3107, a DNA immunotherapy designed to generate T cells capable of targeting HPV-infected cells, in adult RRP patients during a Phase 1/2 trial (NCT04398433). Here, we describe CD4+ T cell responses in these patients.\n\n\n\n\n\n\nüß™ Nature Communications\nMorrow, M. P., Gillespie, E., Sylvester, A., Amin, M. R., Belafsky, P. C., Best, S. R., ‚Ä¶ Wisotsky, S. R., Marcus, S., Reuschel, E. L., Reed, K. S., Weiner, D. B., Dallas, M., Skolnik, J. M. (2025).\nDNA immunotherapy for recurrent respiratory papillomatosis (RRP): Phase 1/2 study assessing efficacy, safety, and immunogenicity of INO‚Äë3107.\nhttps://doi.org/10.1038/s41467-025-56729-6\n\n\n\nAbstract\n\nRecurrent respiratory papillomatosis (RRP) is a chronic airway disease caused by HPV. In this Phase‚ÄØ1/2 study, INO‚Äë3107, a DNA immunotherapy targeting HPV‚Äë6/‚Äë11, was well‚Äëtolerated and showed clinical benefit, reducing surgical interventions in participants and generating antigen‚Äëspecific T‚Äëcell responses that correlated with clinical outcomes.\n\n\n\n\n\n\nüß™ Cancer Immunology Research (AACR)\nGillespie, E., Sylvester, A., Marcus, S., Reed, K., Reuschel, E. L., Wisotsky, S., et al (2024).\nReduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways\nhttps://aacrjournals.org/cancerimmunolres/article/12/10_Supplement/A005/748902\n\n\n\nAbstract\n\nRecurrent respiratory papillomatosis (RRP) is a debilitating chronic disease of the airway caused by Human Papillomavirus (HPV) characterized by recurrent benign tumor growth with the potential for malignant transformation. The current standard of care requires frequent surgeries, the sequalae of which have long-standing negative impacts on airway and vocal function. Treatments that avoid surgery targeted against HPV6 and/or HPV11 (known etiological agents of RRP) are thus an area of need. Here we describe the results of a Phase 1/2 trial of INO-3107, a DNA therapy designed to elicit T-cell responses against HPV-6 and HPV-11, in adults with RRP (NCT04398433). Methods: Peripheral blood mononuclear cells (PBMCs) were assessed by IFNg ELISpot and TCRb sequencing of complementarity determining region 3 (CDR3). Formalin fixed paraffin embedded papilloma tissue obtained prior to INO-3107 treatment as well as at the end of the 52-week study was assessed by RNA sequencing. Data were analyzed using Ingenuity Pathway Analysis (IPA) and R. Overall clinical response (OCR) was defined as a reduction in surgical interventions recorded on study as compared to the year prior to study. Results: The OCR of the trial was 81.3%. Analysis of PBMCs longitudinally across the study via ELISpot confirmed induction of T cell activity specific to HPV-6 as well as HPV-11. TCRb sequencing of CDR3 regions indicated significant T cell clonal expansion in all patients. IPA based assessments indicated a number of significantly enriched immune pathways in airway tissue at the end of study relative to pre-treatment, spanning both innate and adaptive immune responses. For the former, enriched pathways were inclusive of recruitment (z=2.3, p=1.00e-10), migration (z=2.4, p=6.50e-15), quantity (z=2.3, p=1.37e-10), and response (z=3.0, p=5.85e-07) of antigen presenting cells, indicative of an innate inflammatory response. Upregulated genes included macrophage and dendritic cell associated transcripts such as IFNg, CIITA, XCR1, CD14 and others. For the latter, homing (z=2.4 , p=7.77e-06), quantity (z=2.7, p=6.27e-21), signaling (z=3.9, p=3.16e-12), and cytotoxicity (z=2.6, p=1.18e-06), of T cells were all significantly enriched, indicating a robust influx of activated T cells into airway tissue. T cell associated transcripts included CD3D/E/G, PRF1, CD8A, GZMA, and others. Conclusions: INO-3107 provides clinical benefit to adults with RRP, is well tolerated, and generates an antigen-specific immune response against HPV types 6 and 11. In total, 100% of patients on trial demonstrated T cell activity in blood after administration of IN0-3107, inclusive of antigen specific cytokine production and significantly expanded T cell populations. Moreover, treatment induced an inflammatory response in patient airway tissues, inclusive of signatures of macrophages, dendritic cells and T cells. Importantly, this activity was associated with overall clinical response\n\n\n\n\n\n\nüü¢ PLoS ONE\nLucaci, A. G., Wisotsky, S. R., et al.¬†(2021).\nExtra base hits: Widespread empirical support for instantaneous multiple‚Äënucleotide changes.\nhttps://doi.org/10.1371/journal.pone.0248337\n\n\n\nAbstract\n\nThis study provides empirical evidence for instantaneous multiple‚Äënucleotide substitutions across genomic datasets, challenging assumptions of strictly single‚Äënucleotide change models in evolutionary analyses.\n\n\nüü£ Molecular Ecology\nCui, R., Tyers, A. M., Juzar Malubhoy, Z., Wisotsky, S. R., et al.¬†(2021).\nAncestral transoceanic colonization and recent population reduction in a nonannual killifish from the Seychelles archipelago.\nhttps://doi.org/10.1111/mec.15982\n\n\n\nAbstract\n\nPhylogenomic and species distribution evidence supports transoceanic dispersal events and recent population decline in Seychelles killifish, with genomic signals of relaxed developmental gene selection.\n\n\n\n\n\n\nüîµ Molecular Biology and Evolution\nWisotsky, S. R., Kosakovsky Pond, S. L., Shank, S. D., & Muse, S. V. (2020).\nSynonymous site‚Äëto‚Äësite substitution rate variation dramatically inflates false positive rates of selection analyses.\nhttps://doi.org/10.1093/molbev/msaa037\n\n\n\nAbstract\n\nIgnoring synonymous rate variation across sites can inflate false positive detection of natural selection in molecular data. Incorporating this variation improves evolutionary inference reliability.\n\n\nüîµ Molecular Biology and Evolution\nKosakovsky Pond, S. L., Wisotsky, S. R., Escalante, A., et al.¬†(2020).\nContrast‚ÄëFEL: A test for differences in selective pressures at individual sites among clades.\nhttps://doi.org/10.1093/molbev/msaa263\n\n\n\nAbstract\n\nContrast‚ÄëFEL provides a method for identifying differences in selective pressures at specific sequence sites between phylogenetic clades.\n\n\nüîµ Molecular Biology and Evolution\nKosakovsky Pond, S. L., Poon, A. F. Y., Wisotsky, S. R., et al.¬†(2020).\nHyPhy 2.5 ‚Äë A Customizable Platform for Evolutionary Hypothesis Testing.\nhttps://doi.org/10.1093/molbev/msz197\n\n\n\nAbstract\n\nHyPhy 2.5 is a phylogenetic software platform enabling flexible hypothesis testing via molecular evolutionary models.\n\n\n\n\n\n\nüü° Phytopathology\nParker, J. K., Wisotsky, S. R., et al.¬†(2014).\nViability of ‚ÄòCandidatus Liberibacter asiaticus‚Äô prolonged by addition of citrus juice to culture medium.\nhttps://doi.org/10.1094/PHYTO‚Äë10‚Äë13‚Äë0264‚ÄëR\n\n\n\nAbstract\n\nAddition of citrus juice extended viability of the plant pathogen Candidatus Liberibacter asiaticus, improving culture conditions for experimental study."
  },
  {
    "objectID": "posts/papers/index.html#peer-reviewed-publications",
    "href": "posts/papers/index.html#peer-reviewed-publications",
    "title": "Publications",
    "section": "",
    "text": "üü¢ PLoS ONE\nLucaci, A. G., Wisotsky, S. R., et al.¬†(2021).\nExtra base hits: Widespread empirical support for instantaneous multiple-nucleotide changes.\nhttps://doi.org/10.1371/journal.pone.0248337\n\n\n\nAbstract\n\nThis study provides empirical evidence supporting the occurrence of instantaneous multiple-nucleotide substitutions across diverse datasets. The findings challenge assumptions of single-nucleotide substitution models and highlight implications for evolutionary inference.\n\n\n\n\n\n\nüîµ Molecular Biology and Evolution\nWisotsky, S. R., Kosakovsky Pond, S. L., Shank, S. D., & Muse, S. V. (2020).\nSynonymous site-to-site substitution rate variation dramatically inflates false positive rates of selection analyses: ignore at your own peril.\nhttps://doi.org/10.1093/molbev/msaa037\n\n\n\nAbstract\n\nThis paper demonstrates that ignoring synonymous rate variation can dramatically inflate false positive rates in selection analyses. The study emphasizes the importance of incorporating realistic rate heterogeneity into evolutionary models.\n\n\n\nüü¢ PLoS ONE\nMannino, F., Wisotsky, S. R., Kosakovsky Pond, S. L., & Muse, S. V. (2020).\nEquiprobable discrete models of site-specific substitution rates underestimate the extent of rate variability.\nhttps://doi.org/10.1371/journal.pone.0229493\n\n\n\nAbstract\n\nThis work shows that commonly used discrete substitution models underestimate true rate variability across sites, potentially biasing evolutionary inference and model-based conclusions.\n\n\n\nüîµ Molecular Biology and Evolution\nKosakovsky Pond, S. L., Wisotsky, S. R., Escalante, A., et al.¬†(2020).\nContrast-FEL: A test for differences in selective pressures at individual sites among clades.\nhttps://doi.org/10.1093/molbev/msaa263\n\n\n\nAbstract\n\nContrast-FEL introduces a statistical method to test for differences in selective pressures at individual sites across clades, enabling more refined evolutionary hypothesis testing.\n\n\n\nüîµ Molecular Biology and Evolution\nKosakovsky Pond, S. L., Poon, A. F. Y., Wisotsky, S. R., et al.¬†(2020).\nHyPhy 2.5 - A Customizable Platform for Evolutionary Hypothesis Testing.\nhttps://doi.org/10.1093/molbev/msz197\n\n\n\nAbstract\n\nHyPhy 2.5 provides a flexible, extensible computational framework for evolutionary hypothesis testing using phylogenies, supporting a broad range of statistical methods in molecular evolution.\n\n\n\nüü£ bioRxiv (Preprint)\nCui, R., Tyers, A. M., Juzar Malubhoy, Z., Wisotsky, S. R., et al.¬†(2020).\nGenomics of a killifish from the Seychelles islands supports transoceanic island colonization and reveals relaxed selection of developmental genes.\nhttps://doi.org/10.1101/2020.08.03.232421\n\n\n\nAbstract\n\nThis genomic study of a Seychelles killifish species provides evidence supporting transoceanic island colonization and identifies signatures of relaxed selection in developmental genes.\n\n\n\n\n\n\nüü° Phytopathology\nParker, J. K., Wisotsky, S. R., et al.¬†(2014).\nViability of ‚ÄòCandidatus Liberibacter asiaticus‚Äô prolonged by addition of citrus juice to culture medium.\nhttps://doi.org/10.1094/PHYTO-10-13-0264-R\n\n\n\nAbstract\n\nThis study demonstrated that addition of citrus juice to culture media prolongs viability of ‚ÄòCandidatus Liberibacter asiaticus‚Äô, contributing to improved experimental approaches for studying this plant pathogen."
  },
  {
    "objectID": "posts/papers/index.html#research-focus-areas",
    "href": "posts/papers/index.html#research-focus-areas",
    "title": "Publications",
    "section": "Research Focus Areas",
    "text": "Research Focus Areas\n\nEvolutionary model development\n\nStatistical inference of natural selection\n\nSynonymous rate variation and codon models\n\nCancer immunology and epigenetic regulation\n\nBioinformatics and clinical trial data analysis\n\n\nClick ‚ÄúAbstract‚Äù under each entry to expand details."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Sadie Wisotsky",
    "section": "",
    "text": "Publications\n\n\n\nresearch\n\npublications\n\nbioinformatics\n\n\n\n\n\n\n\n\n\nFeb 23, 2026\n\n\nSadie Wisotsky\n\n\n\n\n\n\n\n\n\n\n\n\nHyphy tutorials\n\n\n\ncommunication\n\ntutorials\n\n\n\n\n\n\n\n\n\nFeb 20, 2026\n\n\nSadie Wisotsky\n\n\n\n\n\nNo matching items"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "Hi, I‚Äôm Sadie (Sarah) Rose Wisotsky, a passionate, data-driven bioinformatician with expertise in next-generation sequencing genomic data, data visualizations, and AI/ML techniques. Skilled in clinical trial data analysis, bioinformatics tool development, and cross-functional team collaboration. Proficient in leading teams, developing backend infrastructure, and delivering actionable insights through advanced data analysis and visualization techniques. In my free time I play roller derby, Dungeons and Dragons,\nI‚Äôve worked on clinical trials data at phase I, II, III and pre-clinical. I‚Äôve touched oncological, virlogical\nHere you‚Äôll find examples of projects I‚Äôve done for work, past workshops, and for fun."
  },
  {
    "objectID": "about.html#about-me",
    "href": "about.html#about-me",
    "title": "About",
    "section": "",
    "text": "Hi, I‚Äôm Sadie (Sarah) Rose Wisotsky, a passionate, data-driven bioinformatician with expertise in next-generation sequencing genomic data, data visualizations, and AI/ML techniques. Skilled in clinical trial data analysis, bioinformatics tool development, and cross-functional team collaboration. Proficient in leading teams, developing backend infrastructure, and delivering actionable insights through advanced data analysis and visualization techniques. In my free time I play roller derby, Dungeons and Dragons,\nI‚Äôve worked on clinical trials data at phase I, II, III and pre-clinical. I‚Äôve touched oncological, virlogical\nHere you‚Äôll find examples of projects I‚Äôve done for work, past workshops, and for fun."
  },
  {
    "objectID": "posts/HyPhy-videos/index.html",
    "href": "posts/HyPhy-videos/index.html",
    "title": "Hyphy tutorials",
    "section": "",
    "text": "As part of my time as a postdoc at IGEM in Temple University, I recorded a series of youtube video for the HyPhy software package.\nThis video describe how to use BUSTED[S], a model I developed in graduate school while at NCSU. The paper for which can be read here.\n\nThe rest of the tutorial videos can be found on the HyPhy Youtube."
  },
  {
    "objectID": "posts/papers/index.html#peerreviewed-publications",
    "href": "posts/papers/index.html#peerreviewed-publications",
    "title": "Publications",
    "section": "",
    "text": "üß™ Cancer Immunology Research (AACR) Reuschel, E. L., Sylvester, A., Marcus, S., Wisotsky, S., Dolgoter, A., Reed, K. S., Tan, G. S., Skolnik, J. M., Gillespie, E. (2024). Treatment of Recurrent Respiratory Papillomatosis with DNA immunotherapy INO-3107 induces activation and enrichment of pro-inflammatory CD4+ T cell responses in blood and airways of patients with clinical response\n\n\nAbstract\n\nRecurrent respiratory papillomatosis (RRP) is a chronic, debilitating disease of the airway primarily caused by infection with human papillomavirus (HPV) types 6 and/or 11 and characterized by recurrent, benign tumor growth with potential for malignant transformation. Current standard of care consists of repeated surgical removal of papillomas, which can lead to lasting airway damage and impaired vocal function. Thus, a non-surgical approach to treat RRP is paramount. Previously, we described CD8+ T cell responses associated with clinical response to INO-3107, a DNA immunotherapy designed to generate T cells capable of targeting HPV-infected cells, in adult RRP patients during a Phase 1/2 trial (NCT04398433). Here, we describe CD4+ T cell responses in these patients.\n\n\n\n\n\n\nüß™ Nature Communications\nMorrow, M. P., Gillespie, E., Sylvester, A., Amin, M. R., Belafsky, P. C., Best, S. R., ‚Ä¶ Wisotsky, S. R., Marcus, S., Reuschel, E. L., Reed, K. S., Weiner, D. B., Dallas, M., Skolnik, J. M. (2025).\nDNA immunotherapy for recurrent respiratory papillomatosis (RRP): Phase 1/2 study assessing efficacy, safety, and immunogenicity of INO‚Äë3107.\nhttps://doi.org/10.1038/s41467-025-56729-6\n\n\n\nAbstract\n\nRecurrent respiratory papillomatosis (RRP) is a chronic airway disease caused by HPV. In this Phase‚ÄØ1/2 study, INO‚Äë3107, a DNA immunotherapy targeting HPV‚Äë6/‚Äë11, was well‚Äëtolerated and showed clinical benefit, reducing surgical interventions in participants and generating antigen‚Äëspecific T‚Äëcell responses that correlated with clinical outcomes.\n\n\n\n\n\n\nüß™ Cancer Immunology Research (AACR)\nGillespie, E., Sylvester, A., Marcus, S., Reed, K., Reuschel, E. L., Wisotsky, S., et al (2024).\nReduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways\nhttps://aacrjournals.org/cancerimmunolres/article/12/10_Supplement/A005/748902\n\n\n\nAbstract\n\nRecurrent respiratory papillomatosis (RRP) is a debilitating chronic disease of the airway caused by Human Papillomavirus (HPV) characterized by recurrent benign tumor growth with the potential for malignant transformation. The current standard of care requires frequent surgeries, the sequalae of which have long-standing negative impacts on airway and vocal function. Treatments that avoid surgery targeted against HPV6 and/or HPV11 (known etiological agents of RRP) are thus an area of need. Here we describe the results of a Phase 1/2 trial of INO-3107, a DNA therapy designed to elicit T-cell responses against HPV-6 and HPV-11, in adults with RRP (NCT04398433). Methods: Peripheral blood mononuclear cells (PBMCs) were assessed by IFNg ELISpot and TCRb sequencing of complementarity determining region 3 (CDR3). Formalin fixed paraffin embedded papilloma tissue obtained prior to INO-3107 treatment as well as at the end of the 52-week study was assessed by RNA sequencing. Data were analyzed using Ingenuity Pathway Analysis (IPA) and R. Overall clinical response (OCR) was defined as a reduction in surgical interventions recorded on study as compared to the year prior to study. Results: The OCR of the trial was 81.3%. Analysis of PBMCs longitudinally across the study via ELISpot confirmed induction of T cell activity specific to HPV-6 as well as HPV-11. TCRb sequencing of CDR3 regions indicated significant T cell clonal expansion in all patients. IPA based assessments indicated a number of significantly enriched immune pathways in airway tissue at the end of study relative to pre-treatment, spanning both innate and adaptive immune responses. For the former, enriched pathways were inclusive of recruitment (z=2.3, p=1.00e-10), migration (z=2.4, p=6.50e-15), quantity (z=2.3, p=1.37e-10), and response (z=3.0, p=5.85e-07) of antigen presenting cells, indicative of an innate inflammatory response. Upregulated genes included macrophage and dendritic cell associated transcripts such as IFNg, CIITA, XCR1, CD14 and others. For the latter, homing (z=2.4 , p=7.77e-06), quantity (z=2.7, p=6.27e-21), signaling (z=3.9, p=3.16e-12), and cytotoxicity (z=2.6, p=1.18e-06), of T cells were all significantly enriched, indicating a robust influx of activated T cells into airway tissue. T cell associated transcripts included CD3D/E/G, PRF1, CD8A, GZMA, and others. Conclusions: INO-3107 provides clinical benefit to adults with RRP, is well tolerated, and generates an antigen-specific immune response against HPV types 6 and 11. In total, 100% of patients on trial demonstrated T cell activity in blood after administration of IN0-3107, inclusive of antigen specific cytokine production and significantly expanded T cell populations. Moreover, treatment induced an inflammatory response in patient airway tissues, inclusive of signatures of macrophages, dendritic cells and T cells. Importantly, this activity was associated with overall clinical response\n\n\n\n\n\n\nüü¢ PLoS ONE\nLucaci, A. G., Wisotsky, S. R., et al.¬†(2021).\nExtra base hits: Widespread empirical support for instantaneous multiple‚Äënucleotide changes.\nhttps://doi.org/10.1371/journal.pone.0248337\n\n\n\nAbstract\n\nThis study provides empirical evidence for instantaneous multiple‚Äënucleotide substitutions across genomic datasets, challenging assumptions of strictly single‚Äënucleotide change models in evolutionary analyses.\n\n\nüü£ Molecular Ecology\nCui, R., Tyers, A. M., Juzar Malubhoy, Z., Wisotsky, S. R., et al.¬†(2021).\nAncestral transoceanic colonization and recent population reduction in a nonannual killifish from the Seychelles archipelago.\nhttps://doi.org/10.1111/mec.15982\n\n\n\nAbstract\n\nPhylogenomic and species distribution evidence supports transoceanic dispersal events and recent population decline in Seychelles killifish, with genomic signals of relaxed developmental gene selection.\n\n\n\n\n\n\nüîµ Molecular Biology and Evolution\nWisotsky, S. R., Kosakovsky Pond, S. L., Shank, S. D., & Muse, S. V. (2020).\nSynonymous site‚Äëto‚Äësite substitution rate variation dramatically inflates false positive rates of selection analyses.\nhttps://doi.org/10.1093/molbev/msaa037\n\n\n\nAbstract\n\nIgnoring synonymous rate variation across sites can inflate false positive detection of natural selection in molecular data. Incorporating this variation improves evolutionary inference reliability.\n\n\nüîµ Molecular Biology and Evolution\nKosakovsky Pond, S. L., Wisotsky, S. R., Escalante, A., et al.¬†(2020).\nContrast‚ÄëFEL: A test for differences in selective pressures at individual sites among clades.\nhttps://doi.org/10.1093/molbev/msaa263\n\n\n\nAbstract\n\nContrast‚ÄëFEL provides a method for identifying differences in selective pressures at specific sequence sites between phylogenetic clades.\n\n\nüîµ Molecular Biology and Evolution\nKosakovsky Pond, S. L., Poon, A. F. Y., Wisotsky, S. R., et al.¬†(2020).\nHyPhy 2.5 ‚Äë A Customizable Platform for Evolutionary Hypothesis Testing.\nhttps://doi.org/10.1093/molbev/msz197\n\n\n\nAbstract\n\nHyPhy 2.5 is a phylogenetic software platform enabling flexible hypothesis testing via molecular evolutionary models.\n\n\n\n\n\n\nüü° Phytopathology\nParker, J. K., Wisotsky, S. R., et al.¬†(2014).\nViability of ‚ÄòCandidatus Liberibacter asiaticus‚Äô prolonged by addition of citrus juice to culture medium.\nhttps://doi.org/10.1094/PHYTO‚Äë10‚Äë13‚Äë0264‚ÄëR\n\n\n\nAbstract\n\nAddition of citrus juice extended viability of the plant pathogen Candidatus Liberibacter asiaticus, improving culture conditions for experimental study."
  },
  {
    "objectID": "posts/papers/index.html#theses-dissertations",
    "href": "posts/papers/index.html#theses-dissertations",
    "title": "Publications",
    "section": "Theses & Dissertations",
    "text": "Theses & Dissertations\n\nüéì Wisotsky, S. R. (2019). Statistical Methods and Genomic Data Analyses for Detecting Natural Selection. Ph.D.¬†Dissertation, North Carolina State University.\nhttps://www.proquest.com/openview/d6709c9e0ac6a25b4547fe1937e80fc5/1?pq‚Äëorigsite=gscholar&cbl=18750&diss=y\n\n\n\nAbstract\n\nThis dissertation develops statistical approaches for detecting natural selection in genomic datasets, focusing on model robustness and evolutionary inference techniques."
  }
]